HomeTOP STORIESZenas BioPharma and Royalty Pharma enter into Obexelimab funding agreement for $300M Zenas BioPharma and Royalty Pharma enter into Obexelimab funding agreement for $300M By rogerjudd September 2, 2025 FacebookTwitterPinterestWhatsApp Post Content Previous articleFirefly Aerospace sees a mix of bullish and cautious ratings after the quiet period expirationNext articleCrypto exchange Gemini seeks $317M in IPO latest articles The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds explore more The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds
